Back to List View Graph View

Levodopa

Levodopa, also known as L-DOPA, is a dopamine precursor used as a cornerstone therapy for Parkinson’s disease and other dopamine-responsive movement disorders.

Where the papers sit

12 papers from the last 6 months study levodopa directly · updated from PubMed 16 Nov 2026

  • Motor Effects of Levodopa

    Levodopa’s motor effects are being defined through gait, freezing-of-gait and dopamine-exposure measures in Parkinson’s disease. Cohort analyses examine whether levodopa use relates to freezing, while laboratory studies quantify altered vertical center of mass and muscle synergies. Randomized comparisons test blood dopamine after levodopa–carbidopa–entacapone versus levodopa–benserazide, and nanoparticle or niosomal formulations pursue neuroprotective delivery. The direction is toward more targeted delivery and objective gait endpoints, but clinical benefit beyond motor measurement remains unresolved.

    5 papers · 41.7%

  • Levodopa Therapy in Parkinsonism

    Rare metabolic disease can mimic parkinsonism, while levodopa safety, dyskinesia control and delivery remain separate therapeutic concerns. Glutaryl-CoA dehydrogenase deficiency and glutaric aciduria type 1 highlight genetic diagnosis when presynaptic dopaminergic dysfunction resembles Parkinson’s disease. FAERS comparisons assess levodopa versus pramipexole signals, whereas animal work targets l-dopa-induced dyskinesia. Nanoplatform studies move toward engineered delivery, but the set offers no single validated treatment direction.

    4 papers · 33.3%

  • Levodopa and DBS Effects

    Levodopa and subthalamic nucleus deep brain stimulation are being linked to circuit-level markers of response and wearing-off in Parkinson’s disease. Imaging seeks a radiological signature of levodopa responsiveness, while EEG and grey-matter topology track excitation/inhibition balance and motor-network change. The recurring question is whether neural encoding and functional connectivity can predict treatment benefit or loss of benefit. Evidence remains cohort- and signal-dependent, leaving clinical validation of these biomarkers open.

    3 papers · 25%

levodopa chemical structure

Papers

The 12 papers from the last 6 months that study levodopa directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Motor Effects of Levodopa (5)
  1. Levodopa Use and Characteristics of Freezing-of-Gait in Patients With Parkinson Disease in the NS-Park and PPMI Cohorts. Neurology · 9 Sept 2026 PMID 42715510
  2. Levodopa-induced alterations in vertical center of mass and muscle synergy structure during Parkinsonian gait. Experimental brain research · 24 Aug 2026 PMID 42635765
  3. Span60/Cholesterol Niosomal Formulation as a Transport Vehicle for L-DOPA and Rasagiline Delivery with Potent In Vitro Neuroprotective Effect. Applied biochemistry and biotechnology · 17 Aug 2026 PMID 42606779
  4. Quercetin nanoparticles exhibit a potential therapeutic effect against the neurochemical changes and motor deficits in a rat model of Parkinson's disease. Scientific reports · 5 Aug 2026 PMID 42557291
  5. Comparison of blood dopamine in Parkinson's patients treated with levodopa carbidopa entacapone vs levodopa benserazide: A randomized controlled trial. Medicine · 23 May 2026 PMID 42175483
Levodopa Therapy in Parkinsonism (4)
  1. Glutaric aciduria type 1 presenting with Parkinsonism with presynaptic dopaminergic dysfunction in an adult female: a case report. Neurogenetics · 15 Sept 2026 PMID 42742749
  2. Comparative pharmacovigilance of Levodopa and Pramipexole: a disproportionality analysis of the FAERS database. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 4 Aug 2026 PMID 42550252
  3. A small molecule reduces both parkinsonism and l-dopa-induced dyskinesia in animal models of Parkinson's disease. Science translational medicine · 15 Jul 2026 PMID 42455901
  4. Bioengineered Silicon-Doped Graphdiyne Conjugated with Amino Acid Derivatives for Levodopa Delivery: A DFT-Based Nanoplatform. ACS applied bio materials · 29 Jun 2026 PMID 42372013
Levodopa and DBS Effects (3)
  1. Levodopa and Subthalamic Nucleus Deep Brain Stimulation Modulate Excitation/Inhibition Balance and the Neural Encoding of Isochronous Sequences in Persons With Parkinson's Disease. Annals of the New York Academy of Sciences · 29 Oct 2026 PMID 42954337
  2. Altered functional topology related to the development of wearing-off in Parkinson's disease. Brain research bulletin · 23 Sept 2026 PMID 42778071
  3. Radiological signature of levodopa responsiveness in Parkinson's disease: A data driven approach in a deep brain stimulation cohort. Neurobiology of disease · 7 Sept 2026 PMID 42705502

By study type

Clinical trials (1)
  1. Comparison of blood dopamine in Parkinson's patients treated with levodopa carbidopa entacapone vs levodopa benserazide: A randomized controlled trial. Medicine · 23 May 2026 PMID 42175483
Observational studies and case reports (3)
  1. Glutaric aciduria type 1 presenting with Parkinsonism with presynaptic dopaminergic dysfunction in an adult female: a case report. Neurogenetics · 15 Sept 2026 PMID 42742749
  2. Levodopa Use and Characteristics of Freezing-of-Gait in Patients With Parkinson Disease in the NS-Park and PPMI Cohorts. Neurology · 9 Sept 2026 PMID 42715510
  3. Radiological signature of levodopa responsiveness in Parkinson's disease: A data driven approach in a deep brain stimulation cohort. Neurobiology of disease · 7 Sept 2026 PMID 42705502
Human data, design not indexed (4)
  1. Levodopa and Subthalamic Nucleus Deep Brain Stimulation Modulate Excitation/Inhibition Balance and the Neural Encoding of Isochronous Sequences in Persons With Parkinson's Disease. Annals of the New York Academy of Sciences · 29 Oct 2026 PMID 42954337
  2. Altered functional topology related to the development of wearing-off in Parkinson's disease. Brain research bulletin · 23 Sept 2026 PMID 42778071
  3. Levodopa-induced alterations in vertical center of mass and muscle synergy structure during Parkinsonian gait. Experimental brain research · 24 Aug 2026 PMID 42635765
  4. Comparative pharmacovigilance of Levodopa and Pramipexole: a disproportionality analysis of the FAERS database. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 4 Aug 2026 PMID 42550252
Preclinical: animal, cell and lab studies (4)
  1. Span60/Cholesterol Niosomal Formulation as a Transport Vehicle for L-DOPA and Rasagiline Delivery with Potent In Vitro Neuroprotective Effect. Applied biochemistry and biotechnology · 17 Aug 2026 PMID 42606779
  2. Quercetin nanoparticles exhibit a potential therapeutic effect against the neurochemical changes and motor deficits in a rat model of Parkinson's disease. Scientific reports · 5 Aug 2026 PMID 42557291
  3. A small molecule reduces both parkinsonism and l-dopa-induced dyskinesia in animal models of Parkinson's disease. Science translational medicine · 15 Jul 2026 PMID 42455901
  4. Bioengineered Silicon-Doped Graphdiyne Conjugated with Amino Acid Derivatives for Levodopa Delivery: A DFT-Based Nanoplatform. ACS applied bio materials · 29 Jun 2026 PMID 42372013